Literature DB >> 9455798

CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95).

W D Thomas1, P Hersey.   

Abstract

Previous studies have shown that CD4 T cells are associated with regression in primary melanoma and rejection of tumors in adoptive transfer models. The mechanism by which they mediate their anti-tumor effects remains unclear, and some studies have suggested that Fas ligand (FasL)/Fas interactions were involved. In the present study, we have examined the cytotoxic mechanism involved in CD4 T-cell killing of melanoma cells and, in particular, the role of FasL/Fas interactions in this killing. We show that the CD4 T cells in 4 clones of T cells induced apoptosis in autologous melanoma cells by MHC-restricted mechanisms but lysed an allogeneic melanoma cell by a non-apoptotic mechanism. Melanoma cells expressed both Fas and FasL, but killing of melanoma cells did not involve Fas/FasL interactions. This was shown by a lack of correlation between Fas expression and susceptibility to lysis and by failure of a monoclonal antibody to Fas to block killing by the CD4 T cells, though the latter expressed FasL. Recombinant FasL did not induce killing of melanoma cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9455798     DOI: 10.1002/(sici)1097-0215(19980130)75:3<384::aid-ijc10>3.0.co;2-9

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.

Authors:  H M Zarour; J M Kirkwood; L S Kierstead; W Herr; V Brusic; C L Slingluff; J Sidney; A Sette; W J Storkus
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.

Authors:  M R Hussein; D A H Elsers; S A Fadel; A-E M Omar
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

3.  Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma.

Authors:  M S Shin; W S Park; S Y Kim; H S Kim; S J Kang; K Y Song; J Y Park; S M Dong; J H Pi; R R Oh; J Y Lee; N J Yoo; S H Lee
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

4.  Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.

Authors:  Janine L Oliver; Matthew P Alexander; Allison G Norrod; Irene M Mullins; David W Mullins
Journal:  Pigment Cell Melanoma Res       Date:  2013-04-11       Impact factor: 4.693

5.  The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes.

Authors:  Jerome Kerzerho; Aurélie Schneider; Emmanuel Favry; Florence Anne Castelli; Bernard Maillère
Journal:  J Biol Chem       Date:  2013-04-03       Impact factor: 5.157

6.  Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.

Authors:  S Manici; T Sturniolo; M A Imro; J Hammer; F Sinigaglia; C Noppen; G Spagnoli; B Mazzi; M Bellone; P Dellabona; M P Protti
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

7.  Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes.

Authors:  A Håkansson; B Gustafsson; L Krysander; B Hjelmqvist; B Rettrup; L Håkansson
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

8.  Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells.

Authors:  L Zamai; M Ahmad; I M Bennett; L Azzoni; E S Alnemri; B Perussia
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.